Patient Retention Ads Should Be Larger Part Of DTC Spend, Consultant Says
Executive Summary
Pharmaceutical companies should devote more of their advertising budgets to patient retention and compliance, DTC Perspectives CEO Robert Ehrlich said
You may also be interested in...
Decline In Ad Letters Does Not Signal Leniency By FDA, Agency Says
Although FDA is issuing fewer warning letters, those issued are more likely to signal a potential enforcement action, FDA Associate Commissioner Peter Pitts suggested during the DTC National Conference & Expo in Boston March 30
Disease Awareness Ad Guidance Stresses Need For “Distinct” Messages
The impact of FDA's draft guidance on disease awareness ads will depend upon how willing manufacturers are to allot portions of their advertising budgets to non-branded ads
DTC Future: Firms Could Pool Dollars For Educational Spots; “Got Drugs?”
Pharmaceutical companies should devote more of their advertising budgets to collective disease education efforts, Rx Insight CEO Bob Ehrlich said